In 2013, Norway established a framework “New Method” for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. In this framework, all innovations should undergo HTA before being funded. In April of 2019, the NIPH has released an HTA report for patent foramen ovale closure, antiplatelet or anticoagulation therapy alone for management of cryptogenic stroke commissioned by RHF Forum. Based on this HTA, the RHF Forum will make a decision regarding further implementation of current treatment method.